Claudia P.
- Country
- France
- Department
- Oncology for pediatrics
Research Overview
- MetroWILMS-1906: Phase 1-2 trial evaluating metronomic chemotherapy in patients with relapsed or refractory Wilms tumor
- Phase 3 Non-Inferiority Trial of Vincristine, Actinomycin-D, and Doxorubicin Versus Vincristine, Carboplatin, and Etoposide in Stage IV Pediatric Renal Tumors
- Phase 3 Study of Busulfan, Melphalan, and Chemoimmunotherapy in High-Risk Neuroblastoma Patients with Insufficient Metastatic Response
Data & Insights
Has run more than one trial at 82 of 188 partner sites.
Specializations
Neuroblastoma Research
The investigator specializes in treating high-risk neuroblastoma, with particular focus on developing advanced therapeutic strategies incorporating chemoimmunotherapy and multimodal treatment approaches.
- Induction therapy optimization
- High-dose chemotherapy protocols
- Targeted radiotherapy approaches
Their work includes innovative combinations of targeted therapies including dinutuximab beta immunotherapy.
Renal Tumors
The investigator focuses on treating stage IV childhood renal tumors, with particular expertise in managing cases with pulmonary and non-pulmonary metastases.
- Metastatic response assessment
- Preoperative chemotherapy protocols
- Treatment optimization strategies
Their research encompasses comparative analyses of different therapeutic regimens for metastatic disease.
Wilms Tumor Treatment
The investigator specializes in developing treatments for refractory and relapsed Wilms tumor, with particular emphasis on metronomic chemotherapy approaches.
- Novel therapeutic combinations
- Long-term disease control strategies
- Refractory disease management
Their work focuses on innovative treatment protocols combining multiple therapeutic agents for improved outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.